What was filed
Aurobindo Pharma told the exchanges that PT Aurogen Pharma Indonesia, itself a wholly owned step-down subsidiary of the company, has incorporated a new wholly owned subsidiary named PT Auro Pharm Indonesia. Per the filing, the entity was incorporated on July 1, 2026, with approval from the authorities received on July 9, 2026. Its stated object is to undertake manufacturing operations in Indonesia, within the pharmaceuticals industry.
Structure and consideration
The company holds the new subsidiary in full, subscribed entirely in cash. Because it is a wholly owned step-down subsidiary, it is a related party of Aurobindo, though the filing states the promoters and promoter group have no interest in the transaction. No governmental or regulatory approvals were required, per the disclosure. As a newly incorporated company, it has no turnover or three-year history to report.